This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through March 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Ekso Bionics (EKSO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ekso Bionics (EKSO) delivered earnings and revenue surprises of -18.18% and -2.08%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Ekso Bionics (EKSO) in Focus: Stock Moves 6.6% Higher
by Kaibalya Pravo Dey
Ekso Bionics (EKSO) shares rose nearly 7% in the last trading session, amid huge volumes.
Options Traders Expect Huge Moves in Ekso Bionics (EKSO) Stock
by Zacks Equity Research
Ekso Bionics (EKSO) needs investors to pay close attention to the stock based on moves in the options market lately.
Can The Uptrend Continue for Ekso Bionics Holdings (EKSO)?
by Zacks Equity Research
Investors certainly have to be happy with Ekso Bionics Holdings, Inc. (EKSO) and its short term performance
Why Trump Could Still Be a Threat to Medical Device Stocks
by Zacks Equity Research
The Republican healthcare bill, American Health Care Act (ACHA), which was released earlier this month with the target to repeal the Affordable Care Act (ACA), hasn't found favor with the masses.